These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
    Author: Miyatake S, Martuza RL, Rabkin SD.
    Journal: Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507.
    Abstract:
    Viral vectors used for cancer gene therapy have usually been either replication-incompetent vectors expressing a gene product that leads to the destruction of the tumor or replication-competent vectors that are inherently cytotoxic to the tumor cells. We have sought to combine the attributes of these different approaches using a defective herpes simplex virus (HSV) vector that consists of a defective particle, containing tandem repeats of the HSV thymidine kinase (TK) gene, and a replication-competent, non-neurovirulent HSV mutant as a helper virus. HSV-TK activity in defective vector-infected cells was significantly greater than that in helper virus-infected cells which contained a single copy of HSV-TK. Infection of cells with this defective vector renders them, as well as surrounding uninfected cells, sensitive to killing by ganciclovir. Ganciclovir treatment of C57BL/6 mice bearing TK-defective vector/helper virus-infected subcutaneous GL261 gliomas resulted in significantly decreased tumor size.
    [Abstract] [Full Text] [Related] [New Search]